U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C34H63N5O9
Molecular Weight 685.8921
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEPSTATIN

SMILES

CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O

InChI

InChIKey=FAXGPCHRFPCXOO-LXTPJMTPSA-N
InChI=1S/C34H63N5O9/c1-17(2)12-23(37-33(47)31(21(9)10)39-34(48)30(20(7)8)38-27(42)14-19(5)6)25(40)15-28(43)35-22(11)32(46)36-24(13-18(3)4)26(41)16-29(44)45/h17-26,30-31,40-41H,12-16H2,1-11H3,(H,35,43)(H,36,46)(H,37,47)(H,38,42)(H,39,48)(H,44,45)/t22-,23-,24-,25-,26-,30-,31-/m0/s1

HIDE SMILES / InChI
Pepstatin is a pentapeptide of microbial origin. The peptide inhibits the acid proteases pepsin and cathepsin D and the pressor enzyme renin. Pepstatin was shown to provide long-lasting inhibition (3 to 6 days) of cathepsin D in vivo in non-tumor bearers particularly in spleen, liver, kidney, lung, and heart. Pepstatin may prove useful as "anticachexia" agent by decreasing proteolysis in muscle and other tissues. The in vivo pepstatin and IL-2 treatment decreased the T-cells and increased the natural killer-like LAK precursor cells, possibly also with an increase in its activity, which were further induced by in vitro IL-2 culture to generate an augmented LAK cell activity. This suggests the clinical potential of pepstatin in IL-2-related immunotherapy. In rats injected centrally with the specific cathepsin D inhibitor, pepstatin, the protease activity was inhibited up to 90% in most brain regions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [Ki]
0.5 nM [Kd]
0.13 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs).
2002-09-01
Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines.
2002-08-30
Novel inhibition of porcine pepsin by a substituted piperidine. Preference for one of the enzyme conformers.
2002-08-09
Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo- and heterooligomeric assemblies of the F-box proteins Pop1p and Pop2p.
2002-08-07
Aspartic proteinase in Dugesia tigrina (Girard) planaria.
2002-07-23
Correlation between beta-amyloid peptide production and human APP-induced neuronal death.
2002-07
Microinjection of cathepsin d induces caspase-dependent apoptosis in fibroblasts.
2002-07
Enzymes with gelatinolytic activity can be found in Tityus bahiensis and Tityus serrulatus venoms.
2002-07
Probing the importance and potential roles of the binding of the PH-domain protein Boi1 to acidic phospholipids.
2002-06-27
Complexity of agonist- and cyclic AMP-mediated downregulation of the human beta 1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization.
2002-06-25
Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis.
2002-06-17
Purification and partial amino acid sequences of an esterase from tomato.
2002-06
The regulation of protein synthesis and translation factors by CD3 and CD28 in human primary T lymphocytes.
2002-05-17
Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue.
2002-04-18
Cdc5 influences phosphorylation of Net1 and disassembly of the RENT complex.
2002-04-17
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.
2002-04-08
Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.
2002-04-08
Lens epithelial cell apoptosis and intracellular Ca2+ increase in the presence of xanthurenic acid.
2002-04-05
A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis.
2002-04-01
FAD-linked mutations in presenilin 1 alter the length of Abeta peptides derived from betaAPP transmembrane domain mutants.
2002-03-16
Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D.
2002-03-15
Auto-protective redox buffering systems in stimulated macrophages.
2002-03-12
Endoproteolysis of presenilin in vitro: inhibition by gamma-secretase inhibitors.
2002-03-12
Decreased apoptotic response of inclusion-cell disease fibroblasts: a consequence of lysosomal enzyme missorting?
2002-03-10
Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes.
2002-03-01
Role of Ca2+-dependent metalloprotease-2 in stimulating Ca2+ ATPase activity under peroxynitrite treatment in bovine pulmonary artery smooth muscle membrane.
2002-03
Overexpression, purification, and partial characterization of Saccharomyces cerevisiae processing alpha glucosidase I.
2002-03
Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas.
2002-02-20
Involvement of cathepsin E in exogenous antigen processing in primary cultured murine microglia.
2002-02-15
Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression.
2002-02-01
Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2.
2002-02-01
Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development.
2002-02
Absorption, transportation and digestion of egg white in quail embryos.
2002-02
Molecular cloning of an extracellular aspartic proteinase from Rhizopus microsporus and evidence for its expression during infection.
2002-02
Free-energy analysis of enzyme-inhibitor binding: aspartic proteinase-pepstatin complexes.
2002-01-11
Cell-associated collagenolytic activity by Candida albicans.
2002
Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis.
2002
The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution.
2002
Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases.
2002
Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis.
2002
Pleureryn, a novel protease from fresh fruiting bodies of the edible mushroom Pleurotus eryngii.
2001-12-07
Human muscle protein degradation in vitro by eosinophil cationic protein (ECP).
2001-12
Cathepsin D cleaves aggrecan at unique sites within the interglobular domain and chondroitin sulfate attachment regions that are also cleaved when cartilage is maintained at acid pH.
2001-12
Myocardial enzymatic activity of renin and cathepsin D before and after bilateral nephrectomy.
2001-11
Corpuscles of Stannius secrete renin or an isorenin that regulates cardiovascular function in freshwater North American eels, Anguilla rostrata LeSueur.
2001-11
Biochemical alteration of membrane-associated IL-6 RI (80-kDa) in adherent macrophages and vascular endothelium.
2001-09
Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
2001
Reconstitution of licensed replication origins on Xenopus sperm nuclei using purified proteins.
2001
Generation of choline for acetylcholine synthesis by phospholipase D isoforms.
2001
Cloning, expression and nuclear localization of human NPM3, a member of the nucleophosmin/nucleoplasmin family of nuclear chaperones.
2001
Patents

Sample Use Guides

Mouse: 0.6 mg/kg daily for 3 or 6 days
Route of Administration: Intraperitoneal
In Vitro Use Guide
Pepstatin A was added to the culture medium at a final concentration of 10-4 M in 0.2% DMSO. Pepstatin A had no effects on growing HeLa cells that were not treated with IFN-gamma. Addition of pepstatin A to the IFN-gamma-treated DHFR-transfected cells inhibited, to some extent, the killing process, as reflected by the elevated values of neutral red dye uptake.
Name Type Language
NSC-272671
Preferred Name English
PEPSTATIN
INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
Pepstatin [WHO-DD]
Common Name English
PEPSTATIN [USAN]
Common Name English
pepstatin [INN]
Common Name English
PEPSTATIN A
Common Name English
PEPSTATIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
Code System Code Type Description
FDA UNII
V6Y2T27Q1U
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
MERCK INDEX
m8530
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY Merck Index
CHEBI
7989
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
SMS_ID
100000082520
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
WIKIPEDIA
PEPSTATIN
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
247-600-0
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL296588
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
MESH
C031375
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID7046095
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
EVMPD
SUB09709MIG
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
INN
3316
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
CAS
26305-03-3
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
PUBCHEM
5478883
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
NCI_THESAURUS
C96295
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY
NSC
272671
Created by admin on Mon Mar 31 19:24:31 GMT 2025 , Edited by admin on Mon Mar 31 19:24:31 GMT 2025
PRIMARY